Now showing items 1-2 of 2
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma
(Massachusetts Medical Society, 2010-09-30)
Background The survival rate among patients with intermediate-risk neuroblastoma who receivedose-intensive chemotherapy is excellent, but the survival rate among patients whoreceive reduced doses of chemotherapy for shorter ...
Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue, PSA146-154
(Hindawi Publishing Corporation, 2010)
Twenty eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate specific antigen, PSA146-154, between July 2002 to September ...